Diamyd Medical AB - Class B DMYD B

STO: DMYD B | ISIN: SE0005162880   5/05/2025
9,370 SEK (-7,23%)
(-7,23%)   5/05/2025

21 april 2025 · Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout · Persbericht

9 september 2024 · Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine · Persbericht

30 juli 2024 · Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes · Persbericht

23 juli 2024 · Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd® in Type 1 Diabetes · Persbericht

18 juli 2024 · Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes · Persbericht

12 april 2024 · Recruitment milestone reached in Diamyd® Phase 3 trial · Persbericht

15 februari 2024 · Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd® · Persbericht

8 januari 2024 · Diamyd Medical gains market research findings to guide U.S. commercial strategy · Persbericht

7 november 2023 · Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial · Persbericht

17 oktober 2023 · Diamyd Medical announces a webcast presentation on October 20 regarding its industry partnership with JDRF · Persbericht

5 september 2023 · Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US · Persbericht

4 april 2023 · Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes · Persbericht

10 maart 2023 · Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors · Persbericht

28 november 2022 · US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA · Persbericht

20 september 2022 · Updated results from clinical trial with Diamyd® presented today at diabetes conference · Persbericht

Mijn selecties